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Abstract
Objectives: This study aimed to determine the prevalence of the metabolic syndrome, abnormalities of
liver enzymes and sonographic fatty liver, as well as the inter-related associations in normal weight,
overweight and obese children and adolescents.
Methods: This cross-sectional study was conducted among a sample of 1107 students (56.1% girls), aged
6-18 years in Isfahan, Iran. In addition to physical examination, fasting blood glucose, serum lipid profile
and liver enzymes were determined. Liver sonography was performed among 931 participants. These
variables were compared among participants with different body mass index (BMI) categories.
Results: From lower to higher BMI category, alanine aminotransferase (ALT), total cholesterol, LDL-
cholesterol, triglycerides and systolic blood pressure increased, and HDL-cholesterol decreased
significantly. Elevated ALT, aspartate aminotransferase (AST) and alkaline phosphatase (ALP) were
documented in respectively 4.1%, 6.6% and 9.8% of normal weight group. The corresponding figure was
9.5%, 9.8% and 9.1% in overweight group, and 16.9%, 14.9% and 10.8% in obese group, respectively. In all
BMI categories, ALT increased significantly by increasing the number of the components of the metabolic
syndrome. Odds ratio for elevated liver enzymes and sonographic fatty liver increased significantly with
higher number of the components of the metabolic syndrome and higher BMI categories before and after
adjustment for age.
Conclusions: Because of the interrelationship of biochemical and sonographic indexes of fatty liver with
the components of the metabolic syndrome, and with increase in their number, it is suggested to
determine the clinical impact of such association in future longitudinal studies.
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Introduction
Overweight and obesity in children have become a world-
wide problem, no more limited to high-income countries;
among developing countries, the Middle East has one the
highest rates of childhood obesity [1]. In Iran, the
national prevalence of overweight and obesity among 6-
18-year-old students is reported to be 13.4%, with large
variations between different provinces [2], and as high as
28.9% in students aged 11-18 years in the capital city [3].
Metabolic syndrome, which is a constellation of meta-
bolic abnormalities including insulin resistance, hyperin-
sulinemia, glucose intolerance, dyslipidemia, and
hypertension, is common in overweight youths, affecting
around 30% of overweight children and adolescents in
the United States [4]. It probably plays an important role
in developing type 2 diabetes and atherosclerotic cardio-
vascular diseases [5]. Nonalcoholic fatty liver disease
(NAFLD) is another consequence of obesity and is related
metabolic disorders [6]. Since obesity and diabetes are the
two most common risk factors for NAFLD development,
they can, at least partially, induce peripheral insulin resist-
ance. However, an independent association of NAFLD
with insulin resistance, as suggested by epidemiologic
studies [7], has been confirmed through the use of the
clamp technique. NAFLD includes different ranges of liver
pathologies and outcomes from simple steatosis to nonal-
coholic steatohepatitis (NASH) [6]. The latter could be
more severe in children from special ethnic groups, such
as Hispanics and Asians [8]. NAFLD usually develops in
children who are obese [9]. While abnormalities of liver
enzymes in pediatric NAFLD are moderate [8], a correla-
tion between degree of obesity and severity of hepatic
steatosis at ultrasonography has been reported [9,10].
Among adults, NAFLD markers such as alanine ami-
notransferase (ALT) might predict metabolic syndrome,
independently. Such experience is very limited in the
pediatric age group. A study in children and adolescents
found a strong association of the metabolic syndrome
with elevated ALT levels, and this association existed in a
graded fashion across the number of metabolic compo-
nents [11]. Thus, early diagnosis of overweight in children
is a valuable goal in order to limit obesity development as
soon as possible [8]. Although Asian children are sug-
gested to have an ethnic predisposition to increased waist
circumference [12] and metabolic disorders notably dysl-
ipidemia even in those with normal weight (13, 14), data
about the association of NAFLD and metabolic syndrome
in children are scarce not only in Iran, but in Asia. The
present survey aimed to collect relevant data on the prev-
alence of metabolic syndrome, abnormalities of liver
enzymes and sonographic fatty liver, as well as the inter-
related associations in a representative sample of over-
weight/obese children and adolescents. To the best of our
knowledge, this is the first study of its kind not only in
Iran, but also in the Eastern Mediterranean region, and the
findings might be used for future ethnic comparisons.
Methods
This cross-sectional population-based study was con-
ducted in 2006-2007 in Isfahan, the second large city in
Iran. It met the ethical guidelines of the Declaration of
Helsinki and was approved by the Ethics Committee of
Isfahan Cardiovascular Research Center, Isfahan Univer-
sity of Medical Sciences (ICRC-IUMS) (NIH Code: FWA
0000t8578).
Study population
The target population was school students in Isfahan aged
6 to 18 years. After necessary arrangements with authori-
ties of the Provincial Education and Training office, the
project team selected the students by multistage-random
cluster sampling from elementary, intermediate and high
schools in different areas of Isfahan. Initially, the project
team randomly selected sectors based on the data of the
Provincial Education and Training office. Then, schools
were stratified according to the location within the sec-
tors, taking into account the proportion of different types
of schools (public or private) to avoid socioeconomic
bias. In each randomly selected school, a proportional
two-stage cluster sample of students was selected. Then,
schools were the primary units (clusters) and students
within the schools were the secondary units. Students
were coded and were randomly selected using random
number tables.
Those with mental retardation, any chronic medical prob-
lem, long-term medication use for any health disorder,
signs compatible with genetic syndromes as abnormal
face, history of any kind of infectious or non-infectious
hepatic disorder were not included to the study. As alco-
hol use is forbidden in our country, none of the individu-
als had used alcoholic beverages.
In the first step, weight and height of 7554 randomly
selected students were measured in their schools [15], and
after calculation of their body mass index (BMI.) as weight
(Kg) divided by height squared (m2), they were catego-
rized into three groups of normal weight, overweight
(BMI of 85 to 94th percentile) and obese (BMI equal or
greater than 95th percentile) based on the BMI charts of
the US centers for disease control and prevention [16].
Then a random sample was selected from each BMI group,
and students were included in the study after full explana-
tion of the study protocol and obtaining written informed
consents from parents and oral assents from students. The
whole study was provided free of charge.Diabetology & Metabolic Syndrome 2009, 1:29 http://www.dmsjournal.com/content/1/1/29
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Anthropometric measurements
Selected students were invited to the Pediatric Preventive
Cardiology Department, (ICRC-IUMS). In order to con-
firm the BMI category, height and weight were twice meas-
ured to the nearest 0.2 cm and 0.2 kg, respectively, by
using calibrated scale and stadiometer (Seca, Japan) with
subjects being barefoot and lightly dressed, and the aver-
ages were recorded. The anthropometric measures were in
agreement with those obtained in schools. All measure-
ments were made by the same trained team of general
physicians and nurses under the supervision of the same
pediatrician. After filling out a questionnaire on demo-
graphic characteristics, the waist circumference (WC) was
measured with a non-elastic tape at a point midway
between the lower border of the rib cage and the iliac crest
at the end of normal expiration. Hip circumference (HiC)
was measured at the widest part of the hip at the level of
the greater trochanter to the nearest 0.5 cm.
Blood pressure measurements and biochemical analysis
Blood pressure (BP) was measured using mercury sphyg-
momanometers (Richter, Germany), after 5-minutes of
rest in the sitting position. At this time, the procedure was
explained to the students. They were seated with the heart,
cuff, and zero-indicator on the manometer at the
observer's eye level. All readings were taken in the right
arm. Appropriate size cuffs were used with cuff-width
40% of mid-arm circumference, and cuff bladders cover-
ing 80-100% of the arm circumference and approximately
two thirds of the length of the upper arm without overlap-
ping. The first measured BP was not used in the analysis of
this study. The reading at the first and the fifth Korotkoff
phase was taken as systolic and diastolic BP (SBP and
DBP), respectively. The average of the two time measure-
ments was recorded and included in the analysis.
Then, while one parent accompanied his/her child, fasting
venous blood sample was taken from the antecubital vein
between 8:00 to 9:30 am. Serum fasting blood glucose
(FBG), alanine aminotranferease (ALT), aspartate ami-
notransferase (AST), alkaline phosphatase (ALP), triglyc-
erides (TG), total cholesterol (TC), low and high density
lipoprotein cholesterol (LDL-C, HDL-C) were measured
on fresh samples by standard kits (Pars Azmoun, Tehran,
Iran) by using auto-analyzer (Hitachi, Japan). All Labora-
tory measurements were performed in ICRC central labo-
ratory with adherence to external national and
international quality control.
Sonographic evaluation
Participants were referred to the Radiology ward of Nour
hospital (formerely named Khorshid), affiliated to IUMS.
We have previously reported details of sonographic exam-
ination [17], and here we report it in brief. Children and
adolescents underwent ultrasound examination by two
radiologists by using an ultrasound multi-frequency curvi-
linear 3.5-5 MHZ probe by Siemens Company (Sonoline
G50 series, model number 7474922).
Definition of elevated liver enzymes, metabolic syndrome 
and sonographic fatty liver
According to the study design, we had included nearly
similar proportions of normal-weight, overweight and
obese participants, therefore the percentiles of liver func-
tion tests were determined in a sub-sample of participants
with a BMI distribution similar to the proportions docu-
mented in the whole 7554 students studied with a preva-
lence of 9.34% of overweight and 5.33% of obesity as we
described before [15]. Thus, we randomly selected a simi-
lar proportion of participants from the 1107 individuals
who underwent blood sampling for liver function tests by
including 514 children and adolescents consisting of all
normal-weight (n = 438), 48 overweight and 28 obese
participants. ALT, AST and ALP were considered elevated
if their levels were at or above the 90th percentile value cal-
culated from this sample population.
We used the definition of the International Diabetes Fed-
eration for the metabolic syndrome in children and ado-
lescents [18]. WC above the age- and gender-specific 90th
percentile of Iranian children and adolescents was consid-
ered as abdominal obesity [19]. As described before [16],
sonographic fatty liver was defined as increased echo-
genicity of the liver parenchyma to the extent that it was
reported by ultrasound and disturbed the visibility of the
portal vein and liver artery [20].
Statistical analysis
Data were analysed by SPSS version 15.0 (SPSS Inc., Chi-
cago, USA). Descriptive data were expressed as mean val-
ues ± standard deviations (SD) for continuous variables.
Differences between genders were assessed by Student t
test. The mean values of variables studied were compared
between normal weight, overweight and obese groups by
analysis of variance (ANOVA) and post hoc analysis.
ANOVA and Kruskal Wallis tests were used for compari-
son of mean values of ALT, AST and ALP by the number of
components of the metabolic syndrome in children and
adolescents in the three groups of body mass index.
Correlation of waist circumference and cardio-metabolic
risk factors with liver enzymes was determined according
to sex and body mass index by using Pearson correlation
analysis.
Logistic regression analysis was performed to determine
the risks of elevated liver enzymes and sonographic fatty
liver according to the number of components of the met-
abolic syndrome. The odds ratios (OR) and 95% confi-
dence intervals (CI) for elevated liver enzyme levelsDiabetology & Metabolic Syndrome 2009, 1:29 http://www.dmsjournal.com/content/1/1/29
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according to the number of components of the metabolic
syndrome and according to BMI categories are presented
before and after age-adjustment. P < 0.05 was considered
statistically significant.
Results
The study participants comprised 1107 students including
621(56.1%) girls and 486 (43.9%) boys with a mean
(SD) age of 12.57 (3.3) years. Of them, 331(29.9%) were
in the 6-9.9-year age group, 426(38.5%) and 350(31.6%)
were in the 10-13.9-year and the 14-18-year -age groups,
respectively. Overall 438(39.5%) had normal weight,
377(34%) were overweight and 295(26.6%) were obese.
Of the total population studied, 931 participants includ-
ing 413 (44.4%) boys and 518(55.6%) underwent sonog-
raphy.
The mean value of the variables studied was not signifi-
cantly different in terms of gender; the only significant dif-
ference was documented for liver enzymes: the mean ALT,
AST and ALP were significantly higher in girls than in boys
(19.50 ± 10.4 vs. 17.98 ± 9.74, 24.04 ± 10.5 vs. 22.60 ±
10.15 and 525.43 ± 248.7 vs. 477.49 ± 269.56 U/L,
respectively, p < 0.05).
As presented in Table 1, from lower to higher BMI cate-
gory, anthropometric measures, ALT, total cholesterol,
LDL-C, TG and SBP increased, and HDL-C decreased sig-
nificantly. AST was not significantly different between
normal weight and overweight group, but was signifi-
cantly higher in obese group than in others; DBP was not
significantly different between overweight and obese
groups, but was lower in the normal weight group than in
others. FPG and ALP were not significantly different
between groups. Correlations of waist circumference and
cardio-metabolic risk factors with liver enzymes are pre-
sented in Table 2, and shows significant correlations in
different BMI categories. Elevated ALT, AST and ALP levels
were documented in respectively 4.1%, 6.6% and 9.8% of
normal weight group. The corresponding figure was 9.5%,
9.8% and 9.1% in overweight group, and 16.9%, 14.9%
and 10.8% in obese group, respectively.
Figure 1 shows the mean values of ALT, AST and ALP by
the number of components of the metabolic syndrome in
normal-weight, overweight and obese groups. In all three
BMI categories, ALT increased significantly by increasing
the number of the components of the metabolic syn-
drome. The corresponding figure for AST was significant
only in the overweight group, whereas mean ALP
decreased significantly in the normal weight group.
Table 3 shows that in general, odds ratio for elevated liver
enzymes and sonographic fatty liver increased signifi-
cantly with higher number of the components of the met-
abolic syndrome and higher BMI categories before and
after adjustment for age. Among total study population,
ORs for elevated ALT or elevated AST in children/adoles-
cents with high FBS, high TG and high total cholesterol
were significantly higher than ORs in subjects with none
of these metabolic abnormalities. Whereas, associations
of low HDL-C and high LDL-C with elevated ALT and AST
were not significant.
While in overweight group, ORs for elevated AST or ele-
vated ALT in children/adolescents with high TG were sig-
nificantly higher than ORs in those with normal TG, the
associations between other metabolic variables and ele-
vated ALT, AST and ALP were not significant. In obese
group, ORs for elevated ALT or elevated AST in subjects
Table 1: Characteristics* of the study population according to the body mass index category
Variables Total Normal weight Overweight Obese P
Age (years) 12.57 ± 3.3 12.08 ± 3.5 13.40 ± 3 12.23 ± 3.1 0.1
Weight (Kg) 51.37 ± 19.2 37.46 ± 13.1 56.07 ± 14.3 66 ± 18.7 <.0001
Height (cm) 151.11 ± 14.7 147.28 ± 16.4 154.19 ± 12.7 152.86 ± 13.3 <.0001
Body mass index (Kg/m2) 21.75 ± 5.5 16.65 ± 2.8 23.12 ± 2.9 27.59 ± 3.8 <.0001
Waist circumference (cm) 79.23 ± 14.4 66.71 ± 8.8 82.74 ± 8.8 93.33 ± 10.9 <.0001
Hip circumference (cm) 91.22 ± 14.6 79.84 ± 11.8 95.70 ± 10 102.39 ± 11.3 <.0001
Alanine aminotransferase (U/L) 19.50 ± 10.4 15.87 ± 7.8 19.62 ± 10.6 24.73 ± 11.3 <.0001
Aspartate transaminase (U/L) 24.04 ± 10.5 23.46 ± 9.2 23.33 ± 10.6 25.80 ± 11.8 0.003
Alkaline phosphatase(U/L) 525.43 ± 148.7 534.42 ± 157.6 494.54 ± 148.9 551.26 ± 131.5 0.08
Fasting blood glucose (mg/dL) 82.50 ± 8.6 81.85 ± 8.6 82.52 ± 8.9 83.43 ± 8.2 0.06
Triglycerides (mg/dL) 112.93 ± 55.4 96.66 ± 40.1 110.51 ± 52.9 140.16 ± 66.8 <.0001
Total cholesterol(mg/dL) 169.60 ± 30.9 161.55 ± 26.7 168.12 ± 31.8 183.45 ± 30.9 <.0001
HDL-cholesterol (mg/dL) 45.75 ± 11.8 48.48 ± 13 44.44 ± 10.3 43.38 ± 10.8 <.0001
LDL-cholesterol (mg/dL) 101.74 ± 26.6 94.13 ± 23.5 102.12 ± 27 112.53 ± 26.6 <.0001
Systolic blood pressure (mmHg) 103.39 ± 14.9 97.78 ± 13.3 104.56 ± 13.5 110.13 ± 15.8 <.0001
Diastolic blood pressure(mmHg) 63.85 ± 10.3 61.19 ± 9.1 65.27 ± 10.4 66.01 ± 11 <.0001
*: mean ± standard deviationDiabetology & Metabolic Syndrome 2009, 1:29 http://www.dmsjournal.com/content/1/1/29
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Table 2: Correlation between waist circumference and cardio-metabolic risk factors with liver enzymes according to sex and body 
mass index
Variables Normal weight Group Overweight Group Obese Group Total
Girls Boys All Girls Boys All Girls Boys All Girls Boys All
Waist
Circumfe
rence 
(cm)
ALT 0.013 0.142 0.031 0.115 0.027 0.077 0.028 0.230** 0.152** 0.205** 0.408** 0.306**
AST -0.251** -0.230** -0.249** -0.025 -0.159* -0.078 0.033 -0.440 0.002 -0.089* 0.065 -0.011
ALP -0.308** -0.121 -0.269** -0.305** -0.168* -0.227** -0.332** -0.268** -0.286** -0.216** -0.117** -0.163**
Systolic 
blood 
pressure
(mmHg)
ALT -0.054 -0.118 -0.078 -0.069 0.128 0.048 0.003 0.088 0.072 0.038 0.201** 0.136**
AST -0.248** -0.328** -0.270** -0.124 -0.054 -0.680 -0.265** -0.177 -0.176* -0.197** -0.83 -0.125**
ALP -0.075 -0.147 -0.097 -0.224** -0.258* -0.181** 0.280 -0.142 -0.044 -0.111* -0.173** -0.110**
Diastolic 
blood 
pressure
(mmHg)
ALT -0.018 -0.133 -0.071 -0.199* 0.101 -0.055 0.068 0.127 0.095 -0.031 0.150** 0.060
AST -0.216** -0.307** -0.245** -0.219** -0.081 -0.149* -0.213* 0.025 -0.049 -0.213** 0.028 -0.122**
ALP -0.122 -0.106 -0.127* -0.212** -0.208* -0.178** 0.127 -0.161 -0.020 -0.112* -0.160** -0.124**
Fasting 
blood 
glucose
(mg/dL)
ALT 0.002 0.106 0.044 0.179** 0.051 0.137** -0.048 0.092 0.004 0.068 0.092* 0.086**
AST 0.150* 0.243** 0.181** 0.201** 0.288** 0.244** 0.111 0.159 0.109 0.147** 0.218** 0.181**
ALP 0.051 0.109 0.083 0.200** 0.073 0.171** -0.093 0.022 -0.058 0.053 0.072 0.070*
Triglyceri
des
(mg/dL)
ALT 0.109 0.055 0.087 0.172** 0.129 0.149** 0.271** 0.194* 0.218** 0.239** 0.274** 0.249**
AST 0.101 -0.095 0.036 0.138* 0.217** 0.159** 0.136 0.195* 0.160** 0.113** 0.201** 0.148**
ALP 0.122 -0.020 0.061 0.114 0.086 0.095 0.183* 0.091 0.059 0.135** -0.018 0.077*
Total 
Cholester
ol(mg/dL)
ALT 0.028 0.030 0.023 0.119 0.072 0.099 0.164* 0.127 0.126* 0.155** 0.210** 0.173**
AST 0.059 -0.013 0.028 0.058 0.049 0.055 -0.015 0.158 0.078 0.091 0.136** 0.078**
ALP 0.193** 0.034 0.113* 0.116 0.058 0.092 0.019 0.088 0.042 0.135** 0.055 0.093**
LDL-
C(mg/dL)
ALT 0.098 0.067 0.081 0.116 0.002 0.068 0.035 -0.021 -0.035 0.143** 0.160** 0.144**
AST 0.051 -0.014 0.023 0.037 -0.085 0.010 -0.115 -0.040 -0.052 0.009 0.043 0.020
ALP 0.136* -0.012 0.064 0.085 -0.009 0.056 -0.084 0.069 0.029 0.074 0.013 0.044
HDL-
C(mg/dL)
ALT -0.103 -0.060 -0.088 0.012 -0.108 0.042 0.048 0.040 0.039 -0.067 -0.055 -0.065*
AST 0.006 0.083 0.030 0.032 0.183* 0.083 0.089 0.124 0.110 0.033 0.088 0.052
ALP 0.129* 0.223** 0.157** -0.025 0.171* 0.020 0.066 0.245** 0.140* 0.074 0.207** 0.111**
*:P value < 0.05; ** P value < 0.01 ALT: Alanine aminotransferase (U/L); AST: Aspartate aminotransferase (U/L); ALP: Alkaline phosphatase (U/L)Diabetology & Metabolic Syndrome 2009, 1:29 http://www.dmsjournal.com/content/1/1/29
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Mean (95%CI) of liver enzymes according to the number of components of the metabolic syndrome Figure 1
Mean (95%CI) of liver enzymes according to the number of components of the metabolic syndrome.
P value
                                                                                          Obese :   0.001 **;Overweight :   0.02  *; Normal  weight :  0.44              
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Table 3: Odds ratio for elevated liver enzymes and sonographic fatty liver according to the number of the metabolic syndrome components and categories of body mass index 
before and after adjustment for age
Variables Participants n 
(%) total:1110
Unadjusted for age OR (95% CI) Adjust ed for age OR (95% CI)
Participants 
who 
underwent 
sonogrphy n 
(%) total: 931
Elevated 
ALT
Elevated 
AST
Elevated 
ALP
Fatty liver Elevated 
ALT
Elevated 
AST
Elevated 
ALP
Fatty liver
Number of components of the metabolic syndrome¶
0 210
(18.9%)
183
(19.7%)
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
1 436
(39.3%)
377
(40.5%)
1.06
(0.05, 2.19)
1.73
(0.81,3.70)
1.34
(0.73,2.46)
2.85*
(1.15, 7.06)
1.05
(0.51, 2.17)
1.75
(0.81, 3.74)
1.69
(0.89,3.17)
2.81*
(1.13, 6.98)
2 383
(34.5%)
311
(33.4%)
1.61
(0.79, 3.27)
3.18*
(1.52,6.67)
1.61
(0.87, 2.98)
2.78*
(1.13, 6.85)
1.59
(0.78, 3.2)
3.22*
(1.53,6.78)
2.14*
(1.12, 4.07)
2.76*
(1.12, 6.81)
≥ 3 81(7.3%) 60(6.4%) 3.69*
(1.61, 8.45)
2.71*
(1.05, 7.0)
0.74
(0.25, 2.19)
11.31**
(3.9, 32.81)
3.55*
(1.50,8.38)
2.86*
(1.08, 7.6)
1.49
(0.49,4.59)
9.84**
(3.32, 29.15)
Body mass index categories
Normal 
weight
438
(39.5%)
389
(41.8%)
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Overweight 377
(34.0%)
314
(33.7%)
2.22*
(1.23,4.02)
1.32
(0.79,2.21)
0.87
(0.54,1.41)
10.53**
(3.15, 35.23)
2.19*
(1.20, 3.96)
1.89
(0.79, 2.25)
1.08
(0.66, 1.78)
10.05**
(3.0, 33.62)
Obese 295
(26.6%)
228
(24.5%)
3.41**
(1.87, 6.19)
1.92*
(1.14, 3.25)
1.11
(0.67, 1.85)
121.84**
(37.69, 393.83)
3.41*
(1.87,6.20)
1.34*
(1.12, 3.21)
1.05
(0.62, 1.76)
127.13**
(39.2, 412.26)
¶: The ORs (95% CIs) were calculated by performing logistic regression analysis to determine the risk of elevated ALT according to the number of components of the metabolic syndrome after 
adjustment for age and body mass index.
P value < 0.05; ** P value < 0.01Diabetology & Metabolic Syndrome 2009, 1:29 http://www.dmsjournal.com/content/1/1/29
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with high TG and high total cholesterol were significantly
higher than ORs in those without these metabolic abnor-
malities Relationship between elevated ALT and the
number of the metabolic syndrome components showed
that the prevalence of metabolic syndrome components
in children/adolescents who had ultrasonographic exam-
inations with 0, 1, 2, and ≥ 3 risk factors were 19.7%,
40.5%, 33.4%, and 6.4%, respectively. The unadjusted
ORs for elevated ALT levels in children/adolescents with
1, 2, and ≥ 3 risk factors were 1.06 (95% CI, 0.05-2.19),
1.61 (95% CI, 0.79-3.27), and 3.69 (95% CI, 1.61-8.45),
respectively, that was significant for subjects with ≥ 3 risk
factors. The unadjusted ORs for elevated AST were signifi-
cant in children/adolescents with 2 risk factors [3.18
(95% CI, 1.52-6.67)], and for subjects with ≥ 3 risk factors
[2.71, 95% CI, 1.05-7.0). Both adjusted and unadjusted
ORs for fatty liver were significant in children/adolescents
with 1, 2, and ≥ 3 risk factors. While for elevated ALT, the
adjusted OR was significant only in subjects with ≥ 3 risk
factors [3.69 (95% CI, 1.61-8.45)], for elevated AST it was
significant in children/adolescents with either 2 risk fac-
tors [3.22 (95% CI, 1.53-6.78)], or ≥ 3 risk factors [2.86
(95% CI, 1.08-7.6)]. The adjusted OR for elevated ALP
was significant only in subjects with 2 risk factors [2.14
(95% CI, 1.12-4.07)].
Discussion
Overweight and obese children/adolescents were much
more likely to have elevated ALT, AST and ALP levels than
normal weight children/adolescents in our study, a find-
ing compatible with the results of the third National
Health and Nutrition Examination Survey (NHANES III)
[21]. But the prevalence of elevated ALT in overweight
children in the current study was almost double of that in
NHANES III. Because of the cross-sectional design of the
study, we were not able to define a causal relationship
between metabolic syndrome and the levels of liver
enzymes. However, our findings agreed with a recent pro-
spective study that revealed AST and ALT could independ-
ently predict type 2 diabetes in persons aged 40-69 years
after 5.2 years [22]. Our results showed that overweight or
abdominal obesity was the most sensitive predictor of ele-
vated ALT levels in children/adolescents.
Still the measurement of the WC has not been included in
the routine physical examinations in the clinical and epi-
demiological studies of the pediatric age group. Several
studies have found that WC is a simple and effective indi-
cator that can be used to screen central adiposity [23] as
well as cardiovascular risk profiles [24,25] in children/
adolescents. Oliveira et al. demonstrated that for each 5-
cm increase in WC and every 1-point increase in BMI z-
score, there was a 1.3-fold greater chance of having
increased ALT levels [11]. Then, WC should consider
measuring in adolescents being evaluated for non-viral
and nonalcoholic elevation of aminotransferase levels.
We found that the metabolic syndrome is an important
cause of elevated ALT levels in adolescents. Our study on
a subsample of 100 adolescents aged 12-18 years selected
from the participants of the current study revealed signifi-
cant associations between insulin resistance and NAFLD,
and similar risk factors and protective factors for these two
inter-related disorders [26]. The findings of the current
study agreed with other studies that showed NAFLD
occurs most commonly in conditions associated with
insulin resistance in children [27-29]. Although the ORs
did not represent the biological aggravation of liver func-
tion, our study revealed that the higher the number of
components of the metabolic syndrome, the higher the
risk of elevated ALT or AST. Different studies have shown
that a number of metabolic syndrome components, obes-
ity and insulin resistance are strong predictors of increased
ALT activity in NAFLD in children/adolescents [30-35].
Central obesity, raised TG, reduced HDL, and elevated
fasting glucose are metabolic syndrome components that
contributed to increased ALT activity. Hyperlipidemia,
especially elevated TG concentrations, was a primary risk
factor for NAFLD [28] and was also an outcome of
NAFLD. We found that high TG concentrations were sig-
nificantly associated with elevated ALT, AST and ALP in
children/adolescents. In future interventional studies, in
addition to liver enzymes, high-sensitivity C-reactive pro-
tein, gamma-glutamyl transpeptidase, uric acid, vitamin
D, adiponectin, ghrelin level, insulin levels, insulin resist-
ance and the oral glucose tolerance test could be the inte-
gral part of the evaluation of patients with NAFLD to
further clarify the relationships among different biologic
factors and metabolic syndrome.
The cross-sectional nature of this study does not allow us
to infer causality but rather serves to generate and test
hypotheses. The other limitation was that we could not
examine the insulin level because of the financial limita-
tions for the large number of study participants. Moreo-
ver, IDF has not defined the criteria of the metabolic
syndrome in children aged less than 10 years of age, and
for the whole participants, we applied the IDF definition
for those aged equal or greater than 10 years. We should
also acknowledge that we used biochemical and sono-
graphic findings as surrogate markers of fatty liver, none
of the participants had clinically significant evidence of
hepatosteatosis and we did not confirm fatty liver by his-
tology.
Our findings complement the recent findings about the
relationship of fatty liver with the metabolic syndrome in
children and adolescents, and emphasize on the role of
obesity in this regard. We found that the higher the
number of components of the metabolic syndrome, the
higher the risk of elevated ALT and sonographic fatty liver.Diabetology & Metabolic Syndrome 2009, 1:29 http://www.dmsjournal.com/content/1/1/29
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A recent review suggested that ectopic fat accumulation
(such as visceral and hepatic fat accumulation) has a piv-
otal role in the development of the metabolic syndrome
[36], our findings on the interrelationship of biochemical
and sonographic indexes of NAFLD with the components
of the metabolic syndrome and with increase in their
number is a confirmatory evidence for such association
from early life, it is suggested to determine the clinical
impact of such association in future longitudinal studies.
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